What is the role of immunotherapy in treatment of peanut allergy?. Issue 7 (July 2018)

• Record Type: Journal Article
• Authors: Morris, Carl; Lang, Edith
• Is Part Of: Evidence-based practice. Volume 21:Issue 7(2018)
• Publication Date: 2018-07
• DOI: 10.1097/01.EBP.0000545212.21980.d2
• Languages: English
• ISSNs: 1095-4120

Abstract

Abstract : EVIDENCE‐BASED ANSWER : Oral or sublingual peanut immunotherapy can achieve short‐term desensitization in 60% to 80% of children and adults with peanut allergy (SOR: B, meta‐analysis of small RCTs and a single RCT). In patients continuing immunotherapy for 3 years (after an initial 44 weeks of treatment), tolerance decreases significantly, but can be maintained in responders for up to 8 weeks after discontinuing immunotherapy (SOR: B, single cohort study). Currently, immunotherapy for peanut allergy is considered investigational and is not recommended for routine use (SOR: C, expert opinion).